-+ 0.00%
-+ 0.00%
-+ 0.00%

Avalon Pharma Wins 15-year Exclusive Biosimilar License Deal in Saudi Arabia

MT Newswires·08/18/2026 01:33:07
Listen to the news
01:33 AM EDT, 08/18/2026 (MT Newswires) -- Middle East Pharmaceutical Industries Co. (SASE:4016), d/b/a Avalon Pharma, entered into a 15-year exclusive license contract with biopharmaceutical company Bio-Thera Solutions. The renewable agreement will give the Saudi Arabian pharmaceutical company the exclusive right to register and commercialize Bio-Thera Solutions' proposed Dupixent biosimilar, Dupilumab, in Saudi Arabia, according to a Tuesday release. The company expects the product to be launched in 2031. Additionally, the deal, which was valued at less than 5% of its 2025 revenue, includes the option to localize the production of Dupilumab in the future.